Finch - ESG Rating & Company Profile powered by AI
This article contains a Q&A table about Finch. Check the end of this webpage for potential risks for Finch based on sector, geography and marketcap. Alternative corporations in the scoring industry group for Finch are shown below.
Finch in the N/A industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 3.0, social score of 0.0 and governance score of 3.0.
4.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Finch | 4.0 | High |
... | ... | ... | |
2 | KfW Bankengruppe | 0.0 | Low |
2 | European Investment Bank | 0.0 | Low |
2 | Golden Goose SpA | 0.0 | Low |
2 | The National Exhibition Centre Limited | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Finch have an accelerator or VC vehicle to help deliver innovation?
Does Finch disclose current and historical energy intensity?
Does Finch report the average age of the workforce?
Does Finch reference operational or capital allocation in relation to climate change?
Does Finch disclose its ethnicity pay gap?
Does Finch disclose cybersecurity risks?
Does Finch offer flexible work?
Does Finch have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Finch disclose the number of employees in R&D functions?
Does Finch conduct supply chain audits?
Does Finch disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Finch conduct 360 degree staff reviews?
Does Finch disclose the individual responsible for D&I?
Does Finch disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Finch disclose current and / or historical scope 2 emissions?
Does Finch disclose water use targets?
Does Finch have careers partnerships with academic institutions?
Did Finch have a product recall in the last two years?
Does Finch disclose incidents of discrimination?
Does Finch allow for Work Councils/Collective Agreements to be formed?
Has Finch issued a profit warning in the past 24 months?
Does Finch disclose parental leave metrics?
Does Finch disclose climate scenario or pathway analysis?
Does Finch disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Finch disclose the pay ratio of women to men?
Does Finch support suppliers with sustainability related research and development?
Does Finch disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Finch reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Finch involved in embryonic stem cell research?
Does Finch disclose GHG and Air Emissions intensity?
Does Finch disclose its waste policy?
Does Finch report according to TCFD requirements?
Does Finch disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Finch disclose energy use targets?
Does Finch disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Finch have a policy relating to cyber security?
Have a different question?
Potential Risks for Finch
These potential risks are based on the size, segment and geographies of the company.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.